Data Highlight Medtronic Vascular Innovations at Charing Cross 2017
April 20 2017 - 9:00AM
New Data from
the Global ENGAGE Registry, IN.PACT Admiral
Global Study, and VeClose Study Among Key Presentations
LONDON and DUBLIN - April 20,
2017 - Medtronic plc (NYSE: MDT) today announced key clinical
studies for its leading vascular interventional portfolio will be
featured at the annual 2017 Charing Cross Symposium (CX), one of
the world's largest educational meetings specializing in vascular
and endovascular disease management, in London from April 25-28,
2017. This year, more than 40 presentations, cases and hands-on
demonstration sessions will highlight Medtronic aortic, endoVenous,
and peripheral devices.
The highly anticipated five-year durability data
from the global ENGAGE Registry will be presented on Wednesday,
April 26, 2017. Philippe Cuypers, M.D., of Catharina Hospital in
Eindhoven, The Netherlands will report on the long-term performance
of the Endurant® stent graft system in patients with abdominal
aortic aneurysms (AAA).
Peter Holt, M.D., from St George's University of
London will present on a new analysis that will utilize data from
the ENGAGE Registry to inform clinicians' treatment decisions
following endovascular aneurysm repair (EVAR). In two separate
sessions, Prof. Hence Verhagen, M.D., Ph.D., of University Medical
Center in Rotterdam, The Netherlands and Ross Milner, M.D., of
University of Chicago will present on sub-analyses of complex
patients1 from the
ENGAGE Registry.
New sub-analyses from the IN.PACT Global Study
will be unveiled in two "Podium First" presentations on Tuesday,
April 25, 2017 focusing on real-world patient outcomes, including
the durability, safety, and efficacy of the IN.PACT(TM) Admiral(TM)
drug-coated balloon (DCB) to treat challenging and complex lesions
in patients with peripheral artery disease. Gary Ansel, M.D., of
OhioHealth Riverside Methodist Hospital in Columbus, Ohio, will
present one-year results comparing standard IDE-like patients
versus complex (wider criteria) patient cohorts.
Shortly following, Fabrizio Fanelli, M.D., EBIR,
of Sapienza University of Rome, Italy will share findings from a
subset analysis on the impact of calcification when patients with
complete total occlusions and long lesions are treated with the
IN.PACT Admiral DCB.
The VenaSeal(TM) closure system will be featured
in two key clinical presentations, including the three-year results
of Medtronic's pivotal VeClose study and 12-month results from the
WAVES study, which is an independent, physician-sponsored study.
Both data sets will be presented by Kathleen Gibson, M.D., of Lake
Washington Vascular in Seattle on Tuesday, April 25, 2017. VenaSeal
is a non-tumescent, non-thermal, and non-sclerosant procedure that
uses a proprietary medical adhesive to close superficial veins of
the lower extremities, such as the great saphenous vein (GSV), in
patients with venous reflux.
"With clinical trials and registries that lead the
industry in rigor and comprehensiveness, Medtronic is helping to
create standards of care that underpin durable, consistent, and
safe vascular procedures," said Tony Semedo, president and senior
vice president of Medtronic's Aortic & Peripheral Vascular
division. "We look forward to unveiling the latest clinical
evidence across our interventional therapies at Charing
Cross."
A schedule of selected Medtronic presentations appears below in
chronological order in Greenwich Mean Time.
Tuesday, April 25, 2017
- Drug-Coated Balloon Consensus Update (Upper Main
Auditorium)
- 10:30 a.m.: Podium First: 12-month outcomes of
standard vs. wider usage of DCB - IN.PACT global study; Gary Ansel,
M.D.
- 10:52 a.m.: Podium First: Outcomes of DCB with
calcification, >15 cm, complete total occlusion and TASC C and D
lesions - IN.PACT study; Fabrizio Fanelli, M.D.
- Aortic Edited Cases, Thoracic (Pillar Hall
Learning Centre)
- 11:00 a.m.: The new Valiant Navion device; Ali
Azizzadeh, M.D.
- Varicose Vein Management - INTERVENTION METHOD
and Outcomes (Lower Main Auditorium)
- 2:19 p.m.: Endovenous adhesive vs. radiofrequency
ablation at three years - VeClose study; Kathleen Gibson, M.D.
- 3:12 p.m.: Endovenous adhesive occlusion for
advanced superficial venous disease - WAVES study data at 12
months; Kathleen Gibson, M.D.
- Aortic Edited Cases, Abdominal (Pillar Hall
Learning Centre)
- 4:00 p.m.: Technique for endoanchor in the
primary and secondary situations; Jean-Paul de Vries, M.D.
Wednesday, April 26, 2017
- Venous Edited Cases (Venous City - Exhibition
Level)
- 9:45 a.m.: Performing cyanoacrylate closure
(VenaSeal) of a great saphenous vein; Sudip Ray, M.D.
- Peripheral Edited Cases (Lower Main Auditorium)
- 10:30 a.m.: IN.PACT drug-coated balloon in the
treatment of AV fistula - evidence, tips and tricks; Andrew Holden,
M.D.
- INTERVENTION METHOD (Upper Main Auditorium)
- 10:38 a.m.: Risk and clinical surveillance of
EVAR - Long-term Estimation of Aortic Risk (LEAR); Peter Holt,
M.D.
- 10:46 a.m.: Safety considerations with hostile
neck 10-15mm; Hence Verhagen, M.D.1
- Peripheral Edited and Live Cases (Lower Main
Auditorium)
- 11:30 a.m.: The value of DCB in the popliteal
artery; Koen Deloose, M.D.
- 12:00 p.m.: Combination therapy: directional
atherectomy with HawkOne 6F followed by IN.PACT drug-coated balloon
for the treatment of femoropopliteal lesions; Theodosias Bisdas,
M.D. & Arne Schwindt, M.D.
- Outcomes and Follow-Up (Upper Main Auditorium)
- 12:14 p.m.: ENGAGE registry - five-year
durability data; Philippe Cuypers, M.D.
- Strategies, devices and techniques to optimise
outcomes for endovascular treatment of complex AAAs (Upper Main
Auditorium)
- 12:33 p.m.: Endoanchor in the short
neck1; William
Jordan, M.D.
- 12:42 p.m.: Optimising the outcomes of chEVAR
through a standardisation of patient selection, devices and
technique; Konstantions Donas, M.D.
- Venous Hands-On Workshop (Venous City -
Exhibition Level)
- 9:30 a.m.: ClosureFast; Tristan Lane, M.D. &
Ravinder Singh-Ranger, M.D.
- 9:30 a.m.: VenaSeal; Kathleen Gibson, M.D. &
Supid Ray, M.D.
Thursday, April 27, 2017
- Whether to Intervene (Lower Main Auditorium)
- 8:52 a.m.: A new classification system for
femoropopliteal artery patterns of restenosis; Lawrence Garcia,
M.D.
- INTERVENTION METHOD and Outcomes (Upper
Main Auditorium)
- 2:14 p.m.: Rationale for supra vs. infrarenal
choice1; Ross Milner,
M.D.
- Venous Hands-On Workshop (Venous City -
Exhibition Level)
- 9:30 a.m.: Abre Stent; Erin Murphy, M.D.
In collaboration with leading clinicians,
researchers, and scientists worldwide, Medtronic offers the
broadest range of innovative medical technology for the
interventional and surgical treatment of cardiovascular disease and
cardiac arrhythmias. The company strives to offer products and
services of the highest quality that deliver clinical and economic
value to healthcare consumers and providers around the world.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 88,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
1 In the
U.S., the Endurant II/IIs stent system is approved for neck lengths
>= 10 mm and <= 60° infra-renal angulation.
Contacts:
Krystin Hayward Leong
Public Relations
+1-508-261-6512
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Sep 2023 to Sep 2024